CA2184635A1 - Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic - Google Patents

Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic

Info

Publication number
CA2184635A1
CA2184635A1 CA002184635A CA2184635A CA2184635A1 CA 2184635 A1 CA2184635 A1 CA 2184635A1 CA 002184635 A CA002184635 A CA 002184635A CA 2184635 A CA2184635 A CA 2184635A CA 2184635 A1 CA2184635 A1 CA 2184635A1
Authority
CA
Canada
Prior art keywords
alzheimer
diagnosis
disease
pct
genetic markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002184635A
Other languages
English (en)
Other versions
CA2184635C (fr
Inventor
Philippe Amouyel
Marie-Christine Chartier-Harlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Philippe Amouyel
Marie-Christine Chartier-Harlin
Institut Pasteur
Institut Pasteur De Lille
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philippe Amouyel, Marie-Christine Chartier-Harlin, Institut Pasteur, Institut Pasteur De Lille, Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Philippe Amouyel
Publication of CA2184635A1 publication Critical patent/CA2184635A1/fr
Application granted granted Critical
Publication of CA2184635C publication Critical patent/CA2184635C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

L'invention a pour objet l'utilisation conjointe d'au moins deux marqueurs génétiques choisis parmi APOE, D19S178 et APO CII pour le diagnostic de la maladie d'Alzheimer, en particulier les allèles APO .epsilon.4, APO CII long (30+/-3 motifs répétitifs (CA)) et D19S178 court (moins de 167+/-4 nucléotides). L'invention a également pour objet un procédé de diagnostic de la maladie d'Alzheimer ainsi qu'un kit pour la mise en oeuvre du procédé.
CA002184635A 1994-03-07 1995-03-06 Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic Expired - Fee Related CA2184635C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9402603 1994-03-07
FR9402603A FR2716894B1 (fr) 1994-03-07 1994-03-07 Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
PCT/FR1995/000259 WO1995024504A1 (fr) 1994-03-07 1995-03-06 Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic

Publications (2)

Publication Number Publication Date
CA2184635A1 true CA2184635A1 (fr) 1995-09-14
CA2184635C CA2184635C (fr) 2008-11-18

Family

ID=9460754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002184635A Expired - Fee Related CA2184635C (fr) 1994-03-07 1995-03-06 Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic

Country Status (9)

Country Link
US (1) US5942392A (fr)
EP (1) EP0749498B1 (fr)
JP (1) JP3662585B2 (fr)
AT (1) ATE169343T1 (fr)
CA (1) CA2184635C (fr)
DE (1) DE69503885T2 (fr)
DK (1) DK0749498T3 (fr)
FR (1) FR2716894B1 (fr)
WO (1) WO1995024504A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
ES2128265B1 (es) * 1997-06-04 2000-03-01 Euroespes S A Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CA2297005A1 (fr) * 1997-09-12 1999-03-25 Anthony David Smith Procede permettant de determiner la propension a developper tardivement la maladie d'alzheimer
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
EP1001037A3 (fr) * 1998-09-28 2003-10-01 Whitehead Institute For Biomedical Research Pre-selection et isolement d'un polymorphisme de mononucleotide
ATE225405T1 (de) * 1999-07-09 2002-10-15 Pasteur Institut Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit
ATE422671T1 (de) * 2002-07-30 2009-02-15 David Gladstone Inst Verfahren zur diagnose von morbus alzheimer
EP1623996A1 (fr) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Procédé amélioré de selection d'une protéine desirée d'une bibliothéque.
EP1876244A4 (fr) * 2005-04-04 2009-09-23 Asubio Pharma Co Ltd Calcul du risque relatif de survenue d'une dermité atopique par analyse du polymorphisme génique
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
ES2404311T3 (es) 2005-04-12 2013-05-27 454 Life Sciences Corporation Métodos para determinar variantes de secuencias usando secuenciación ultraprofunda
CN101680027A (zh) * 2007-03-16 2010-03-24 454生命科学公司 检测hiv耐药变异体的系统和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法

Also Published As

Publication number Publication date
US5942392A (en) 1999-08-24
DK0749498T3 (da) 1999-05-10
DE69503885D1 (de) 1998-09-10
FR2716894B1 (fr) 1996-05-24
WO1995024504A1 (fr) 1995-09-14
CA2184635C (fr) 2008-11-18
JPH09511138A (ja) 1997-11-11
EP0749498B1 (fr) 1998-08-05
FR2716894A1 (fr) 1995-09-08
JP3662585B2 (ja) 2005-06-22
DE69503885T2 (de) 1999-04-22
ATE169343T1 (de) 1998-08-15
EP0749498A1 (fr) 1996-12-27

Similar Documents

Publication Publication Date Title
CA2184635A1 (fr) Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic
FR2727117B1 (fr)
CA2316808A1 (fr) Lapin transgenique exprimant une lipoproteine (a) humaine fonctionnelle
WO2002085285A3 (fr) Methodes et compositions permettant de reguler la formation osseuse et cartilagineuse
EP0818744A3 (fr) Procédé de sélection des compositions médicamenteuses potentielles
CA2174315A1 (fr) Modulation par les oligonucleotides de la proteine associee a la resistance multiples aux anticancereux
BG102016A (en) Method for the diagnostics of schizophrenia
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
EP1163515A4 (fr) Outils diagnostiques et therapeutiques permettant de traiter les troubles de la tolerance glucidique
AU2003291287A1 (en) Apkc isoforms in nervous system disorders and cancer
WO2000029623A3 (fr) Acides nucleiques contenant des polymorphismes d'un seul nucleotide et utilisations de ces acides nucleiques
WO2002022871A3 (fr) Gene humain de l'osteoporose
WO2002081745A3 (fr) Genes impliques dans l'osteogenese et procedes d'utilisation associes
AU5137498A (en) Iga nephropathy-associated gene
EP0769957A4 (fr) Procedes de traitement des deficits moteurs
EP1019092A4 (fr) Outils therapeutiques et diagnostiques pour desordres lies a une mauvaise tolerance glucidique
CA2370666A1 (fr) Une isoforme de la tenascine-c comme marqueur de neoplasies
AU1405899A (en) Treatment for alzheimer's disease
WO2001007644A3 (fr) Genotypage du gene de la paraoxonase i pour le pronostic, le diagnostic et le traitement d"une maladie
AU2676695A (en) Method and probes for detecting markers bound to the locus of child spinal muscular atrophies
AU3166295A (en) Imidazopyridine-azolidinones
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
BG102878A (en) The use of genetic change in the gene of the human g-protein, 3-subunit for the diagnostics of diseases
PT648836E (pt) Transactivador do mhc de classe ii (ciita) e suas utilizacoes
WO2001053538A3 (fr) Methode permettant de cartographier un reseau de genes de la maladie d'alzheimer et d'identifier des agents destines au traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130306